A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
- PMID: 11843990
A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting
Abstract
Objectives: To evaluate the safety and efficacy of donepezil in the management of patients with Alzheimer's disease (AD) residing in nursing home facilities.
Design: Twenty-four-week, randomized, multicenter, parallel-group, double-blind, placebo-controlled trial.
Setting: Twenty-seven nursing homes across the United States.
Participants: Two hundred eight nursing home patients with a diagnosis of probable or possible AD, or AD with cerebrovascular disease; mean Mini-Mental State Examination (MMSE) score 14.4; mean age 85.7.
Measurements: The primary outcome measure was the Neuropsychiatric Inventory-Nursing Home Version (NPI-NH). Secondary efficacy measures were the Clinical Dementia Rating (Nursing Home Version)-Sum of the Boxes (CDR-SB), MMSE, and the Physical Self-Maintenance Scale (PSMS). Safety was monitored by physical examinations, vital signs, clinical laboratory tests, electrocardiograms (ECGs), and treatment-emergent adverse events (AEs).
Results: Eighty-two percent of donepezil- and 74% of placebo-treated patients completed the trial. Eleven percent of donepezil- and 18% of placebo-treated patients withdrew because of AEs. Mean NPI-NH 12-item total scores improved relative to baseline for both groups, with no significant differences observed between the groups at any assessment. Mean change from baseline CDR-SB total score improved significantly with donepezil compared with placebo at Week 24 (P < .05). The change in CDR-SB total score was not influenced by age. Differences in mean change from baseline on the MMSE favored donepezil over placebo at Weeks 8, 16, and 20 (P < .05). No significant differences were observed between the groups on the PSMS. Overall rates of occurrence and severity of AEs were similar between the two groups (97% placebo, 96% donepezil). Gastrointestinal AEs occurred more frequently in donepezil-treated patients. In general, AEs were similar in older and younger donepezil-treated patients, with the majority of patients experiencing only AEs that were transient and mild or moderate in severity. Weight loss was reported as an AE more frequently in older patients, although a loss at last visit of >or=7% of screening weight occurred at the same rate in older and younger patients (9% of donepezil- and 6% of placebo-treated patients). No significant differences between groups in vital sign changes, bradycardia, or rates of clinically significant laboratory or ECG abnormalities were observed.
Conclusion: Patients treated with donepezil maintained or improved in cognition and overall dementia severity in contrast to placebo-treated patients who declined during the 6-month treatment period. The safety and tolerability profile was comparable with that reported in outpatient studies of donepezil. These findings also suggest that advanced age, comorbid illnesses, and high concomitant medication usage should not be barriers to donepezil treatment. Given the apparent improvement in behavior in the placebo group, and the high use of concomitant medications in both groups, the impact of donepezil on behavior in the nursing home setting is unresolved and merits further investigation. In summary, effects on cognition, overall dementia severity, and safety and tolerability findings are consistent with previous findings in outpatients and support the use of donepezil in patients with AD who reside in nursing homes.
Comment in
-
Donepezil for nursing home patients with dementia: a reinterpretation of the evidence.J Am Geriatr Soc. 2003 Jan;51(1):132; author reply 132-3. doi: 10.1034/j.1601-5215.2002.51022.x. J Am Geriatr Soc. 2003. PMID: 12534859 No abstract available.
-
Getting donepezil into the nursing home.J Am Geriatr Soc. 2003 Jan;51(1):133-4; author reply 134. doi: 10.1034/j.1601-5215.2002.51024.x. J Am Geriatr Soc. 2003. PMID: 12534861 No abstract available.
Similar articles
-
Donepezil for dementia due to Alzheimer's disease.Cochrane Database Syst Rev. 2018 Jun 18;6(6):CD001190. doi: 10.1002/14651858.CD001190.pub3. Cochrane Database Syst Rev. 2018. PMID: 29923184 Free PMC article. Review.
-
Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial.Neurology. 2009 May 5;72(18):1555-61. doi: 10.1212/01.wnl.0000344650.95823.03. Epub 2009 Jan 28. Neurology. 2009. PMID: 19176895 Clinical Trial.
-
Donepezil preserves cognition and global function in patients with severe Alzheimer disease.Neurology. 2007 Jul 31;69(5):459-69. doi: 10.1212/01.wnl.0000266627.96040.5a. Neurology. 2007. PMID: 17664405 Clinical Trial.
-
Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo-controlled trial.Int J Geriatr Psychiatry. 2005 Jun;20(6):559-69. doi: 10.1002/gps.1325. Int J Geriatr Psychiatry. 2005. PMID: 15920715 Clinical Trial.
-
Perspectives in the management of Alzheimer's disease: clinical profile of donepezil.Dement Geriatr Cogn Disord. 1998;9 Suppl 3:29-42. doi: 10.1159/000051201. Dement Geriatr Cogn Disord. 1998. PMID: 9853200 Review.
Cited by
-
Repurposing non-pharmacological interventions for Alzheimer's disease through link prediction on biomedical literature.Sci Rep. 2024 Apr 15;14(1):8693. doi: 10.1038/s41598-024-58604-8. Sci Rep. 2024. PMID: 38622164 Free PMC article.
-
Alzheimer's Disease: Models and Molecular Mechanisms Informing Disease and Treatments.Bioengineering (Basel). 2024 Jan 1;11(1):45. doi: 10.3390/bioengineering11010045. Bioengineering (Basel). 2024. PMID: 38247923 Free PMC article. Review.
-
Changes in Antidementia Medications upon Admission to the Nursing Home: Who Decides and Why? Results From a National Survey of Nursing Home Administrators.J Am Med Dir Assoc. 2024 Jan;25(1):41-46.e5. doi: 10.1016/j.jamda.2023.09.022. Epub 2023 Oct 28. J Am Med Dir Assoc. 2024. PMID: 38173265
-
Effect of Nordic Sensi® Chair on Behavioral and Psychological Symptoms of Dementia in Nursing Homes Residents: A Randomized Controlled Trial.J Alzheimers Dis. 2023;96(4):1609-1622. doi: 10.3233/JAD-230391. J Alzheimers Dis. 2023. PMID: 38007648 Free PMC article. Clinical Trial.
-
Antidementia Medication Use in Nursing Home Residents.J Geriatr Psychiatry Neurol. 2024 May;37(3):194-205. doi: 10.1177/08919887231202948. Epub 2023 Sep 16. J Geriatr Psychiatry Neurol. 2024. PMID: 37715795
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical